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During the past decade, studies on the composition of human microbiota and its relation
to  the host became one of the most explored subjects of the medical literature. The devel-
opment of high-throughput molecular technologies allowed a deeper characterization of
human microbiota and a better understanding of its relationship with health and disease.
Changes in human habits including wide use of antimicrobials can result in dysregulation of
host–microbiome homeostasis, with multiple consequences. The purpose of this review is
to  highlight the most important evidence in the literature of host–microbiome interactionsHuman and  illustrate how these intriguing relations may lead to new treatment and prevention
strategies.
©  2014 Elsevier Editora Ltda. All rights reserved.
fully cultured and the majority of them are classiﬁed withinIntroduction
The term microbiota refers to an abundant and diverse pop-
ulation of microorganisms such as bacteria and fungi that
reside on body sites, with the highest concentration of these
organisms found in the gastrointestinal tract. Indeed, humans
harbor a complex community of microorganisms that out-
numbers human cells by tenfold.1
Standard culture techniques are limited to fully charac-
terize microorganisms within the microbiota, but nowadays,
modern molecular techniques termed metagenomics are
available to allow deep characterization of the microbiota
of the nasal mucosa, oropharynx, skin, urogenital sites, and
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1413-8670/© 2014 Elsevier Editora Ltda. All rights reserved.lower intestine. These methods rely on polymerase chain reac-
tion ampliﬁcation of 16S ribosomal RNA-encoding genes of the
microbiota, followed by DNA sequencing.2
Projects such as the Human Microbiome Project3 have
already done much to deﬁne the variability in the micro-
biota from different body sites and in the microbiomes both
within the same human subject and among different subjects.
By applying metagenomics, it is estimated that the human
lower intestinal microbiota contains at least 1800 genera and
15,000–36,000 species, most of which have never been success-– 7◦ andar, CEP 04231-030 São Paulo, SP, Brazil.
Firmicutes and Bacteroidetes phyla.4
The human intestinal microbiota matures over the ﬁrst
year of life and has substantial and continuous effects
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Table 1 – Reviews addressing diseases and biologycal phenomena related to human microbiome.
Topics Effect of microbiota Ref.
Inﬂammatory bowel
diseases
In individuals with a genetic susceptibility to inﬂammatory bowel diseases, abnormal microbial
colonization of the gastrointestinal tract might be the origin of such dysregulation.
8
Diabetes and obesity Studies show the effect of gut microbiota on host metabolism by improving energy yield from
food and modulating dietary or the host-derived compounds that alter host metabolic pathways.
9
Neuropsychiatric illness Recent advances in our understanding of how the intestinal microbiota communicates with the
brain via this axis to inﬂuence brain development and behavior. This extended communication
system might inﬂuence a broad spectrum of diseases, including irritable bowel syndrome,
psychiatric disorders, and demyelinating conditions such as multiple sclerosis.
10
Colorectal cancer Potential mechanisms of bacterial oncogenesis are presented, focus is given to the oncogenic
capabilities of enterotoxigenic Bacteroides fragilis
11
Asthma Host’s innate sensing systems, combined with recently developed methods that characterize
commensal and pathogenic microbial exposure, now allow a uniﬁed theory for how microbes
cause mucosal inﬂammation in asthma.
12
Rheumatic diseases Microbiota may be involved in the pathogenesis of rheumatic diseases including altered epithelial
and mucosal permeability, loss of immune tolerance to components of the indigenous microbiota,
and trafﬁcking of both activated immune cells and antigenic material to the joints.
13
Antibiotic resistance Horizontal gene transfer in gut has the potential to inﬂuence the evolution of members of this
 the 
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pmicrobial community and to mediate
organisms to potential pathogens.
n human health and physiological development, including
ietary and nutritional processing,5 prevention of pathogen
nvasion,6 and immune system maturation (Table 1).7
hanging  in  microbiota
uman behavior inﬂuences the composition of microbiota
nd its continuous changes may be responsible for the modi-
cation of the ancient microbiota. Some authors believe that
iseases succeed and fail in response to mankind’s advances.
he appearance and disappearance of infectious and chronic
iseases might be related to changes in human ecology, result-
ng in changes in the microbes that populate our bodies.15
Human civilizations experienced many  transformations,
s improvement in sanitization that was implemented to
educe transmission of infections. In order to provide food
or an increasing population, food production incorporated
ew strategies, such as extensive use of pesticides, antibiotics,
nd hormones in animals and agriculture.15,16 The increas-
ng antibiotic use in humans and farming is one of the most
mportant fact that leads to a rapid and sometimes irreversible
hange on human microbiota.17
Helicobacter pylori is an example of an ancient human micro-
iota member that presented a dramatic change. H. pylori has
een extensively investigated by Dr. Blaser et al. who observed
hat this bacterium was progressively disappearing during the
wentieth century, from individuals in developed countries,
ith secondary alterations in gastric secretory, hormonal and
mmune physiology.18
This bacterium is thought to be related to peptic ulcer and
astric cancer but the sustained acidity in H. pylori-negative
osts increases the risk of gastroesophageal reﬂux disease
nd its consequences, including esophageal and gastric cardia
denocarcinomas.19The stomach also produces adipokine hormones known as
hrelin and leptin, both with multiple roles in energy homeo-
tasis. Patients under antibiotic treatment that eliminated H.
ylori had increased circulating ghrelin levels.20 There is aspread of antibiotic resistance genes from commensal
hypothesis that in recent generations of children growing up
in developed countries, there has been little gastric H. pylori-
mediated regulation of those adipokines at the developmental
stage, when long-term adiposity is being programmed. It is
possible that the disappearance of H. pylori might be con-
tributing to the current epidemics of early-life obesity, type
2 diabetes and related metabolic syndromes.
Gordon et al. were also interested in studying the rela-
tionship between obesity and microbiome. They analyzed
fecal samples of lean and obese twins and observed that
obesity was associated with phylum-level changes in the
microbiota, reduced bacterial diversity and altered represen-
tation of bacterial genes, and metabolic pathways related to
glycoside hydrolases.21 Cardiovascular risk also has inﬂuence
on intestinal microbial metabolism, as shown by Hazen et
al., who observed an increase in a proatherosclerotic metabo-
lite, trimethylamine-N-oxide (TMAO), in healthy participants
after the suppression of intestinal microbiota with oral broad-
spectrum antibiotics.22
Stimulation of the immune system is another impor-
tant function of the microbiome where the disruption of
immune homeostasis may be associated with inﬂamma-
tory and atopic diseases.23 Epidemiological studies show that
H. pylori-positive individuals have lower risk of childhood
asthma, allergic rhinitis and skin allergies than those with-
out H. pylori.24 H. pylori-positive stomach has a rich population
of immune cells which regulates immune functions. Stom-
achs of H. pylori-negative hosts have much lower number of
these cells, which have systemic, as well as local activities.25
The increase in prevalence of immunological disorders (both
of autoimmune and of atopic origin) in the developed world
has been associated with changes in microbiome, which gave
support to the hygiene hypothesis.26Microbiome  and  infectious  diseases
The relationship between the microbiome and infectious dis-
eases has yet to be determined. There is a lot of interest
i s . 2 0
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regarding the effect of antibiotic therapy, as antibiotic treat-
ment to prevent or eradicate a pathogenic infection also
impacts the composition of the commensal microbiota.
Combined antibiotic therapy with clarithromycin and
metronidazole reduced bacterial diversity of healthy subjects
in short and long terms.27 A decline trend was observed in
Actinobacteria in both throat and feces immediately after
treatment. The microbiota remained perturbed in some cases
for up to four years post treatment.27 The effect of two courses
of ciproﬂoxacin therapy was analyzed by another study. A pro-
found and rapid shift in community composition occurred
within three to four days of drug initiation, with a loss of
bacterial diversity. One week after the end of each course,
communities returned incompletely to their initial state.28
The consequences of antibiotic therapy might be difﬁcult to
understand as the microorganisms that are affected may not
be those that are directly targeted by the antibiotic. A com-
plex network of co-dependence exists among members of the
microbiota, driven by different ways. One intriguing interac-
tion was described by Hogan et al.29 that described a quorum
sensing molecule (3-oxo-C12 homoserine lactone), produced
by Pseudomonas aeruginosa,  that inhibits Candida albicans ﬁla-
mentation and its virulence in vitro.
The microbiota has also protective functions. A mouse
model for S. typhimurium diarrhea was used to study the role
of microbiota and secretory antibodies (sIgA). When exposed
o infection, mice that harbor a low complexity gut ﬂora, lack
S. typhimurium colonization resistance and develop a normal
sIgA response, but fail to clear it from the gut lumen. In these
mice, pathogen clearance was achieved by transferring a nor-
mal  complex microbiota. This study was able to determinate
the capacity of microbiota to confer colonization resistance
and to mediate pathogen clearance in primary infections,
despite sIgA.30
Clostridium difﬁcile-associated diarrhea (CDAD) is possibly
one of the most important examples in vivo on how antibi-
otics affect the resident microbial ecosystem patient health.
Endogenous microbial inhabitants provide colonization resis-
tance to infection by other microbes, most notably C. difﬁcile.
Until now the therapeutic option for CDAD relies on antibi-
otic treatment with vancomycin or metronidazole, but this
approach was associated with depletion of host microbiota
and recurrence of symptoms in 35% of patients.31 Transplan-
tation of indigenous microbiota was tested as an alternative
treatment to restore the microbiota of a patient with CDAD.
Not surprising, the intestinal microbiota transplantation
approach resulted in resolution rate of 94%, statistically supe-
rior to vancomycin-containing regimens (p < 0.01).32
Use of probiotic is an intervention that seeks the
restoration of the beneﬁcial microbiota. Strategies are being
implemented following antibiotic therapy in infants with
necrotizing enterocolitis (NEC),33 as well as in individuals
being treated for antibiotic associated diarrhea,34 and bacte-
rial vaginosis.35
Understanding the importance of microbiome is also
critical given the huge number of microorganisms in this
ecosystem, and the possibility of gene transfer between
species. Transfer of resistance genes may occur through
horizontal gene transfer (HGT) from commensal bacteria
to opportunistic pathogens, as previously described CTX-M 1 4;1  8(6):660–663
extended-spectrum beta-lactamase (ESBL) resistance genes,
which originate from Kluyvera sp.36 Using functional metage-
nomic methods, Sommer et al.37 studied individuals after
antibiotic treatment and found clones conferring resistance to
13 different antibiotics and enabled the discovery of 95 unique
inserts containing functional antibiotic resistance genes. The
majority of these genes were evolutionarily distant from
known resistance genes, including 10 previously unidentiﬁed
beta-lactamase gene families.
Because of the harmful effects of antibiotics on the
commensal microbiota, alternative therapies are under
investigation, as antimicrobial peptides that have potential
antibiotic adjunctive action. For instance, a reduced produc-
tion of the antimicrobial peptide REG3 was related to an
increased colonization by vancomycin-resistant Enterococcus
(VRE) in mice. This was a consequence of depleted microbial
signals38 in activating Toll-Like Receptors (TLR). This mecha-
nism seems to be involved in bacterial-mediated protection
from diseases, including VRE, suggesting that TLR agonists
could be administered during antibiotic therapy to help restore
immune homeostasis, speciﬁcally REG3 expression, drasti-
cally reducing colonization by VRE.39
The challenge of efﬁcient control strategies for multidrug
resistant organisms (MDROs) brought the attention for the
hypothesis that restoring and maintaining the commensal
microbiome may be a key to prevent MDRO colonization and
infection.40 Conversely, a comprehensive antimicrobial stew-
ardship program focusing the prevention of MDRO  emergence
is needed. In an attempt to identify antibiotics that promote
KPC colonization, Perez et al.41 evaluated whether antibiotics
promote colonization by KPC-producing Klebsiella pneumonia
(KPC-Kp). They found that those antibiotics that fully suppress
anaerobes and bacteroides (i.e. tigecycline, clindamycin and
piperacillin-tazobactam) promoted signiﬁcant colonization by
KPC-Kp, whereas agents that did not suppress total anaerobes
or bacteroides (i.e., ertapenem, ciproﬂoxacin and cefepime) did
not.41
With an increasing number of studies demonstrating that
antibiotics have detrimental effects on the host health and on
host colonization there is urgent need to develop treatments
targeting speciﬁc pathogens without changing the indige-
nous microbiota. For this, a better understanding on microbial
cross-talking is essential. Most of the studies are still experi-
mental and remain to be validated, but they hold substantial
promise as adjunct therapies to antibiotics in a promising
future.
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